Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Share-based Compensation (2018 - 2025)

Inmune Bio's Share-based Compensation history spans 8 years, with the latest figure at $3.0 million for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 73.59% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $2.5 million, down 67.32%, while the annual FY2024 figure was $1.8 million, 75.86% down from the prior year.
  • Share-based Compensation for Q3 2025 was $3.0 million at Inmune Bio, up from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.0 million in Q3 2025 and bottomed at -$4.1 million in Q4 2024.
  • The 5-year median for Share-based Compensation is $1.7 million (2022), against an average of $1.5 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 184.09% in 2021 before it crashed 316.55% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.5 million in 2021, then increased by 14.91% to $1.7 million in 2022, then rose by 7.43% to $1.9 million in 2023, then crashed by 316.55% to -$4.1 million in 2024, then soared by 173.33% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Share-based Compensation are $3.0 million (Q3 2025), $1.5 million (Q2 2025), and $2.1 million (Q1 2025).